How do you define patient-centered drug development and how does it impact the people you represent?

Test Name
Test Title, Test Company

Read biography×

How do you define patient-centered drug development and how does it impact the people you represent?

Susan Manzi
Chair of the Department of Medicine, Allegheny Health Network

Read biography×

Susan Manzi
Chair of the Department of Medicine, Allegheny Health Network

Follow Susan on:

Dr. Manzi is Co-Director of the Lupus Center of Excellence and serves as Chair of the Department of Medicine of West Penn Allegheny Health System. She is a Vice Chair and Professor at Temple University.

Dr. Manzi graduated magna cum laude from the University of Notre Dame where she was elected to Phi Beta Kappa and Alpha Epsilon Delta honor societies. She received her medical degree from the University of Pittsburgh School of Medicine where she was elected to Alpha Omega Alpha (AOA), the national medical honor society, and received the Jack Myers Medical Alumni Award at graduation for excellence in exemplifying medical ideals. Dr. Manzi completed her medical internship and residency at Duke University Medical Center where she was appointed Assistant Chief Resident, after which she completed her fellowship in rheumatology at University of Pittsburgh Medical Center, and received her master’s degree in public health from the University of Pittsburgh Graduate School of Public Health.

Dr. Manzi has been named one of the "Best Doctors in America" and one of the "Best 100 Doctors in Pittsburgh." She is recognized nationally and internationally as a leader in lupus patient care and research, and a pioneer in scientific investigation of cardiovascular disease in patients with systemic lupus erythematosus (SLE). Dr. Manzi has served on a number of study sections and currently is a member of the Clinical and Integrative Cardiovascular Sciences Study Section for the National Institutes of Health (NIH). She is the Secretary/Treasurer of the Systemic Lupus International Cooperating Clinics Committee, and a member of the Board of Directors, and the Medical Advisory Committee of the Lupus Foundation of America. She has participated in the design and implementation of many phase I, phase II and phase III clinical trials and her expertise in this area has led to her appointment to the FDA Arthritis Advisory Board and six data safety monitoring boards for NIH intramural and extramural programs.

She has served in numerous leadership roles nationally and internationally including Clinical Chair for the American College of Rheumatology Annual Meeting Planning Committee. She has also appeared several times on ABC TV’s Good Morning America and was recognized by the Pittsburgh Business Times as a “Fast Tracker,” one of the regions 50 front-runners. In 2006 she spoke on lupus advocacy at the Fortune 500 Summit in Las Vegas and was elected as delegate to the Fortune 500 “Most Powerful Women in America.”

She has an extensive national and international patent portfolio with exclusive licensing of lupus biomarker technology to Cypress Biosciences, Inc., in San Diego, CA with the intent to commercialize the technology over the next several years. In recognition of these accomplishments, Dr. Manzi received the Pitt Innovator Award in both 2005 and 2006. Dr. Manzi has been the recipient of millions of dollars in research funding from the NIH and other agencies. She has published more than 100 reports of research in lupus and related diseases.

 

×

How do you define patient-centered drug development and how does it impact the people you represent?

Eric Hargis
CEO, Colon Cancer Alliance

Read biography×

Eric Hargis
CEO, Colon Cancer Alliance

Follow Eric on:

Mr. Eric Hargis joined the Colon Cancer Alliance as CEO in January 2014.  Hargis has more than 35 years of relevant leadership experience in national health organizations and has a proven track record of supporting these entities through strategic growth. Hargis has a proven track record of being a transformational leader.  Nationally, he has successfully led the development of numerous programs, partnerships, events and fundraising initiatives.

Daily, Hargis beats the drum that colon cancer is largely preventable and a unique cancer that we can actually do something about.  His passionate approach is intentionally driving the mission of the Colon Cancer Alliance to the forefront of a national health movement.  He is active in FDA committee hearings advocating for innovations in screening, meeting with congressional representatives to provide supportive insight and securing national corporate partnerships. 

Hargis graduated with a degree from the University of San Diego.  He lives in Maryland with his wife and two children.

The Colon Cancer Alliance’s mission is to knock colon cancer out of the top three cancer killers. This mission is being accomplished by championing prevention, funding cutting-edge research and providing the highest quality patient support services. Learn more at ccalliance.org.

 

×

How do you define patient-centered drug development and how does it impact the people you represent?

Todd Gillenwater
Executive Vice President, CLSA

Read biography×

Todd Gillenwater
Executive Vice President, CLSA

Follow Todd on:

Todd E. Gillenwater serves as Executive Vice President – Advocacy & External Relations, leading CLSA’s federal, state and local government relations, policy, alliance development and communications activities. Previously, he served as California Healthcare Institute’s interim President and CEO from Jan. 2014 – Dec. 2014. Gillenwater first joined CHI as Vice President – Public Policy in March 2004. In Dec. 2010, Gillenwater was promoted to Senior Vice President – Public Policy. In that capacity, Gillenwater was responsible for managing CHI’s Washington, D.C. office where he directed the organization’s federal government relations advocacy and outreach activities across issues including U.S. Food and Drug Administration (FDA) and Medicare policies, intellectual property, science research funding, science and math education and tax policy. Prior to joining CHI, Gillenwater was Legislative Director for Congressman David Dreier (R-California), Chairman of the House Rules Committee. In that position, Gillenwater guided the congressman’s legislative work in major policy areas including healthcare, tax policy, and science and technology. In particular, he worked on Medicare, drug importation, stem cell research, NIH funding, and other legislative issues relevant to the biotechnology, pharmaceutical, medical device and academic research communities. Prior to serving on Rep. Dreier’s staff, Gillenwater was an Associate at The Heritage Foundation. Gillenwater holds a master’s degree in management from the Catholic University of America in Washington D.C., and a bachelor’s degree in international relations from Georgia Institute of Technology in Atlanta.

×

How do you define patient-centered drug development and how does it impact the people you represent?

Jon Retzlaff
Managing Director of Science Policy and Government Affairs, AACR

Read biography×

Jon Retzlaff
Managing Director of Science Policy and Government Affairs, AACR

Follow Jon on:

Before joining the American Association for Cancer Research in 2010 as the managing director of science policy and government affairs, Jon Retzlaff led the health and biomedical practice for a government relations firm in Washington, D.C. Prior to these two positions, he served as legislative director for the Federation of American Societies for Experimental Biology from 2004-2007. Additionally, Retzlaff worked for the National Institutes of Health from 1993 to 2004 in various legislative and management positions, which also included being assigned to the House (1998) and Senate (2000-2001) appropriations subcommittees on labor, health and human services, education and related agencies, as well as within the Office of the Secretary for Legislation at the Department of Health and Human Services (1999). He entered the federal government as a Presidential Management Fellow in 1993. Retzlaff earned a Bachelor of Science degree from the University of Minnesota, a master's degree in public administration from Indiana University, and a master's degree in business administration from the Massachusetts Institute of Technology.

×

06/17/14: As Americans live longer, how can we tackle aging as a major risk factor for chronic disease?

Back to Top

Contributors:

                
Bob Blancato , Executive Director, NANASP
Cynthia A. Bens, Vice President, Public Policy, Alliance for Aging Research
Dorothy Leone-Glasser, President and CEO, ARxC
Jamesetta Smith, President, Lupus Foundation AR
Paul Downey, President and Chief Executive Officer, Serving Seniors
Thair Phillips, President, RetireSafe
Rob Gundermann, Public Policy Director, ADAW
James Adams, Chairman, Granite State Taxpayers

Join The Conversation

06/11/14: How are patients with chronic conditions who have exchange coverage affected by high out-of-pocket costs for medicines?

Back to Top

Contributors:

                
Margaret Barton-Burke, President, ONS
Angela Ostrom, VP, Public Policy & Advocacy, Epilepsy Foundation
Carl Schmid, Deputy Executive Director, The AIDS Institute
Virginia T. Ladd, President , AARDA
Brian Hujdich, Executive Director, HealthHIV
Bob Blancato , Executive Director, NANASP
Lawrence A. LaMotte, Vice President, Public Policy, Immune Deficiency Foundation
Colon Cancer Alliance, Colon Cancer Alliance, Colon Cancer Alliance

Join The Conversation

06/05/14: We all want to better prevent, treat and cure the many forms of cancer. How close is the collaborative research ecosystem to achieving these goals, and what do we have to do to get there?

Back to Top

Contributors:

      
Josh Schafer, MSc. MBA, Vice President, Oncology Global Marketing Strategy, Astellas Pharmaceuticals
Rafael Amado, Senior Vice President, Oncology R&D, GlaxoSmithKline
Salvatore Alesci , VP, Scientific & Regulatory Affairs, PhRMA

Join The Conversation

Pages